About Mazence
Mazence is a company based in Suwon (South Korea) founded in 2008 was acquired by KT&G in December 2011. Mazence operates in a competitive market with competitors including Adocia, BioAge Labs, Carmot, Fractyl and Altimmune, among others.
- Headquarter Suwon, South Korea
- SectorsHealthcare
- Website mazence.com
- Acquired by KT&G (Dec 2011)
Investors in Mazence
Mazence has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include KT&G.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tobacco products, ginseng, pharmaceuticals, and health goods are manufactured. | 1987 | ktng.com | Daejeon, South Korea |
Investor details for Mazence
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Mazence
2 dated milestones of Mazence across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Mazence is founded.
- Exit Acquired by KT&G.
Competitors of Mazence
Mazence operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adocia, BioAge Labs, Carmot, Fractyl and Altimmune, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adocia.com | 2005 | Lyon, France | $26M | – | Therapeutics for diabetes and obesity treatment are developed. | |
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. | |
| carmot.us | 2008 | Berkeley, United States | $385.52M | – | Disease-modifying therapies for metabolic diseases are developed. | |
| fractyl.com | 2010 | Lexington, United States | $345.27M | 79 | Endoscopic procedures for type-2 diabetes treatment are developed. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. | |
| orexigen.com | 2002 | San Diego, United States | $76M | 132 | Developing and marketing drugs for the treatment of obesity. | |
| aardvarktherapeutics.com | 2017 | San Diego, United States | $138M | 10 | Small molecule therapeutics for obesity and metabolic disorders are developed. | |
| ranitherapeutics.com | 2012 | San Jose, United States | $234.14M | – | Technology for oral delivery of large drug molecules is developed. | |
| vivus.com | 1991 | Mountain View, United States | – | 59 | Developer of therapeutic solutions for obesity and sexual health |
Detailed competitors of Mazence
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Mazence
Websites that share an audience with Mazence (mazence.com).
Websites whose visitors overlap most with Mazence. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Similar companies to Mazence
10 companies that operate in the same segment as Mazence (Metabolic Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Developer of cortisol modulators for the treatment of various diseases | 1998 | Menlo Park, California, United States | – | USD 761.41 M | 500 | |
Developer of therapies for the treatment of endocrine-related diseases and cancers | 2008 | San Diego, California, United States | USD 103.5 M | USD 1.04 M | 437 | |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | 2009 | Cambridge, Massachusetts, United States | USD 685 M | – | 81 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Solutions for biomarker discovery and diagnostic testing are provided. | 2000 | Morrisville, United States | USD 165.87 M | – | – | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Mazence
Mazence was founded in 2008.
Mazence is headquartered in Suwon, South Korea. It is registered at Suwon, Gyeonggi, South Korea.
Mazence was established in 2008 in Suwon-si, South Korea, as a pharmaceutical entity. Small molecule combination formulations were created by the company to target metabolic conditions, including obesity, diabetes, and metabolic syndrome, along with neurodegenerative and mitochondrial dysfunction diseases. Operations centered on drug development in these therapeutic areas. The company was acquired by KTG on December 27, 2011, for USD 25.95 million.
Mazence's top competitors include Adocia, BioAge Labs and Fractyl.
Mazence has 1 investor. Key investors include KT&G.
Yes. Mazence was acquired by KT&G in December 2011.